Exocrine system

Salivary Bioscience Studies That Have Impact: Getting Back to Our ABCDs

Retrieved on: 
Wednesday, May 12, 2021

"\nAlthough COVID-19 has dominated much of the story of saliva over the last year, the ABCD study is a reminder that Salivary Bioscience makes a positive impact outside of COVID-19.

Key Points: 
  • "\nAlthough COVID-19 has dominated much of the story of saliva over the last year, the ABCD study is a reminder that Salivary Bioscience makes a positive impact outside of COVID-19.
  • Baseline data, such as the association between body mass index and hormone levels, has already been generated from this study.
  • "Salimetrics is ready with the experience and the latest knowledge in salivary bioscience," says Dr. Gaitonde.
  • "\nSalimetrics\' assay kits and CLIA-certified testing services are used to measure salivary analytes related to stress, behavior and development, inflammation, sleep, reproduction, health and immune function.

UroLift® System, a proven treatment for Benign Prostatic Hyperplasia (BPH), now reimbursed in France

Retrieved on: 
Thursday, March 11, 2021

It is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 50 years or older.

Key Points: 
  • It is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 50 years or older.
  • The UroLift permanent implants, delivered during an outpatient procedure, relieve prostate obstruction without cutting, heating, or removing prostate tissue.
  • The Prostatic Urethral Lift procedure (using the UroLift System) is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines.
  • Teleflex is the home of Arrow, Deknatel, Hudson RCI, LMA, Pilling, Rusch, UroLift System and Weck trusted brands united by a common sense of purpose.

InventHelp Inventor Develops Hygienic Tool for Removing Dried Mucus (CTK-2035)

Retrieved on: 
Wednesday, December 9, 2020

The patent-pending invention provides an effective way to clear dried mucus from the nasal passages.

Key Points: 
  • The patent-pending invention provides an effective way to clear dried mucus from the nasal passages.
  • In doing so, it eliminates the need to remove dried mucus with a finger.
  • As a result, it enhances sanitation and safety and it could help to reduce the spread of germs.
  • The invention features a practical design that is convenient and easy to use so it is ideal for the general population.

Another Salivary Bioscience Breakthrough: Research Study Obtains 100% Sensitivity and Specificity for COVID-19 Serology with Support from Salimetrics

Retrieved on: 
Tuesday, November 24, 2020

The significance of this COVID-19 serology study was featured recently in a news release from the Johns Hopkins Bloomberg School of Public Health .

Key Points: 
  • The significance of this COVID-19 serology study was featured recently in a news release from the Johns Hopkins Bloomberg School of Public Health .
  • "We've supported over 20,000 studies, and that experience has put Salimetrics at the leading edge of salivary bioscience methods.
  • This study illustrates that saliva, and how to collect it right, can facilitate widespread, scalable surveillance with uncompromised sensitivity and specificity through practical, non-invasive sampling.
  • "Supported with key scientific knowledge from Salimetrics, this study provides one more step to enable future research and application."

Oyster Point Pharma Announces Clinical Data Presentations on OC-01 Nasal Spray for Dry Eye Disease at the American Academy of Ophthalmology 2020 Virtual Annual Meeting

Retrieved on: 
Friday, November 13, 2020

Goblet cells in the conjunctiva are responsible for releasing mucus and, based on clinical data, may help re-establish tear film homeostasis.

Key Points: 
  • Goblet cells in the conjunctiva are responsible for releasing mucus and, based on clinical data, may help re-establish tear film homeostasis.
  • The data from this clinical study show how parasympathetic activation may stimulate mucin production at the ocular surface.
  • The single-center, randomized, double-masked, placebo-controlled trial included 18 patients with dry eye disease.
  • Oyster Point Pharmas lead product candidate, OC-01 nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease.

The North America pulmonary devices market is expected to reach US$ 16,637.44 million by 2027 from US$ 7,581.04 million in 2019

Retrieved on: 
Thursday, October 29, 2020

Additionally, strategic activities by manufacturers and increasing preference of home care products are likely to fuel the growth of the pulmonary devices market during the forecast period.

Key Points: 
  • Additionally, strategic activities by manufacturers and increasing preference of home care products are likely to fuel the growth of the pulmonary devices market during the forecast period.
  • Pulmonary or respiratory devices are used to remove mucus and secretions from the respiratory tract.
  • These medical devices are focused on diagnosis, control, treatment, management, and evaluation of the problems associated with respiratory tract.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Enterprise Therapeutics’ First-in-Class TMEM16A potentiator program for treatment of cystic fibrosis and other respiratory diseases acquired by Roche

Retrieved on: 
Wednesday, October 7, 2020

The TMEM16A portfolio is focused toward treating all people with cystic fibrosis (CF), with potential to benefit people with other severe respiratory diseases characterised by excessive mucus congestion.

Key Points: 
  • The TMEM16A portfolio is focused toward treating all people with cystic fibrosis (CF), with potential to benefit people with other severe respiratory diseases characterised by excessive mucus congestion.
  • Dr John Ford, CEO, Enterprise Therapeutics, said: Roche and Genentech have a proven track record of bringing new medicines to people with respiratory diseases, and have recognised the opportunity that our TMEM16A potentiator portfolio presents.
  • Dr James Sabry, MD, PhD, Global Head of Pharma Partnering, Roche, commented: We are excited to add Enterprises TMEM16A potentiator program to our existing respiratory portfolio.
  • Moelis acted as financial advisor and Goodwin Procter acted as legal counsel to Enterprise Therapeutics.

NeoTract Designates Dr. Richard Bevan-Thomas as UroLift® Center of Excellence

Retrieved on: 
Tuesday, September 8, 2020

The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

Key Points: 
  • The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.
  • The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.
  • "This designation recognizes Dr. Richard Bevan-Thomas as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH," said Dave Amerson, president of the Teleflex Interventional Urology business unit.
  • Teleflex is the home of Arrow, Deknatel, Hudson RCI, LMA, Pilling, Rusch, UroLift and Weck trusted brands united by a common sense of purpose

Profound Medical Announces First Quarter 2020 Financial Results

Retrieved on: 
Thursday, May 7, 2020

On March 4, 2020, Profound presented at Cowen and Companys 40th Annual Health Care Conference.

Key Points: 
  • On March 4, 2020, Profound presented at Cowen and Companys 40th Annual Health Care Conference.
  • On April 3, 2020, Profound launched a TULSA procedure website, www.tulsaprocedure.com , as a resource for patients with prostate disease.
  • As at May 7, 2020, Profound had an unlimited number of authorized common shares with 16,082,577 common shares issued and outstanding.
  • Profound Medical is pleased to invite all interested parties to participate in a conference call today, May 7, 2020, at 4:30 pm ET during which time the results will be discussed.

Nanocraft Releases First CBD Product Infused with Ingredients Clinically Proven to Boost Immunity

Retrieved on: 
Friday, April 17, 2020

LA JOLLA CALIFORNIA, April 17, 2020 (GLOBE NEWSWIRE) -- NanoCraft, a company creating hemp-derived CBD products for the athletic market, has released a first-of-its-kind softgel containing an active ingredient clinically proven to boost immunity and provide respiratory support.

Key Points: 
  • LA JOLLA CALIFORNIA, April 17, 2020 (GLOBE NEWSWIRE) -- NanoCraft, a company creating hemp-derived CBD products for the athletic market, has released a first-of-its-kind softgel containing an active ingredient clinically proven to boost immunity and provide respiratory support.
  • The powerful ingredients boost natural killer (NK) cells and increase sIgA antibodies to block pathogens from entering the mucus membrane.
  • NanoCraft blends these immune boosters with their highly bioavailable, broad spectrum CBD to round out the perfect capsule.
  • While this new product is taking the market by storm, NanoCraft CBD isnt surprised by the high demand.